PMID- 22082482
OWN - NLM
STAT- MEDLINE
DCOM- 20120518
LR  - 20190923
IS  - 1875-5666 (Electronic)
IS  - 1566-5240 (Linking)
VI  - 12
IP  - 1
DP  - 2012 Jan
TI  - The emerging role of endocrine disruptors in pathogenesis of insulin resistance: 
      a concept implicating nonalcoholic fatty liver disease.
PG  - 68-82
AB  - Endocrine disruptors or endocrine-disrupting chemicals (EDCs) represent a highly 
      heterogeneous group of molecules found in the environment or in consumer 
      products. Toxicology and epidemiology studies have suggested the involvement of 
      diverse EDCs in an increasing number of metabolic disorders, including insulin 
      resistance (IR) and IR-related co morbidities, such as obesity, type 2 diabetes 
      mellitus (T2DM) and polycystic ovary syndrome. Nonalcoholic fatty liver disease 
      (NAFLD), another IR related condition, is emerging as a significant public health 
      concern, affecting 30-45% of the general population in the Western world. To 
      evaluate whether EDCs may also play a role in the pathogenesis of NAFLD, we 
      reviewed the literature on well-studied EDCs, such as dioxins, bisphenol A, 
      phthalates and other persistent organic pollutants, in relation to pathways that 
      might contribute to the pathogenesis of fatty liver / NAFDL. Certain EDCs may be 
      responsible for inducing alterations similar to those encountered in NAFLD either 
      directly through a hepatotoxic effect and/or indirectly by triggering hepatic and 
      systematic IR. Considering these effects, which act in concert with the effects 
      of the epidemics of obesity and T2DM, EDCs may play a significant role in the 
      pathogenesis of fatty liver, thereby increasing the prevalence of NAFLD 
      worldwide. Translational studies and clinical trials investigating the 
      association between EDCs and NAFLD are required to confirm and extent these 
      studies.
FAU - Polyzos, S A
AU  - Polyzos SA
AD  - Department of Medicine, Second Medical Clinic, Aristotle University of 
      Thessaloniki, Ippokration Hospital, Thessaloniki, Greece. stergios@endo.gr
FAU - Kountouras, J
AU  - Kountouras J
FAU - Deretzi, G
AU  - Deretzi G
FAU - Zavos, C
AU  - Zavos C
FAU - Mantzoros, C S
AU  - Mantzoros CS
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Mol Med
JT  - Current molecular medicine
JID - 101093076
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Dioxins)
RN  - 0 (Endocrine Disruptors)
RN  - 0 (Environmental Pollutants)
RN  - 0 (Phenols)
RN  - 0 (Phthalic Acids)
RN  - MLT3645I99 (bisphenol A)
SB  - IM
MH  - Animals
MH  - Benzhydryl Compounds
MH  - Dioxins/pharmacology/toxicity
MH  - Endocrine Disruptors/pharmacology/*toxicity
MH  - Energy Metabolism/drug effects
MH  - Environmental Pollutants/pharmacology/*toxicity
MH  - Fatty Liver/*chemically induced
MH  - Humans
MH  - *Insulin Resistance
MH  - Non-alcoholic Fatty Liver Disease
MH  - Phenols/pharmacology/toxicity
MH  - Phthalic Acids/pharmacology/toxicity
EDAT- 2011/11/16 06:00
MHDA- 2012/05/19 06:00
CRDT- 2011/11/16 06:00
PHST- 2011/05/12 00:00 [received]
PHST- 2011/09/03 00:00 [revised]
PHST- 2011/09/05 00:00 [accepted]
PHST- 2011/11/16 06:00 [entrez]
PHST- 2011/11/16 06:00 [pubmed]
PHST- 2012/05/19 06:00 [medline]
AID - BSP/CMM/E-Pub/00013 [pii]
AID - 10.2174/156652412798376161 [doi]
PST - ppublish
SO  - Curr Mol Med. 2012 Jan;12(1):68-82. doi: 10.2174/156652412798376161.